(Q38406889)

2 September 2017

Velaglucerase alfa in the treatment of Gaucher disease type 1 (English)

1 reference

2 September 2017

1 reference

Thomas A Burrow

1

1 reference

PMC publication ID

3172711

2 September 2017

Gregory A Grabowski

series ordinal

2

1 reference

2 September 2017

1 February 2011

1 reference

2 September 2017

Clinical investigation

1 reference

2 September 2017

1

1 reference

2 September 2017

2

1 reference

2 September 2017

285-293

1 reference

Early achievement and maintenance of the therapeutic goals using velaglucerase alfa in type 1 Gaucher disease

2 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3172711

Comparative therapeutic effects of velaglucerase alfa and imiglucerase in a Gaucher disease mouse model

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3172711

Characterization of gene-activated human acid- -glucosidase: Crystal structure, glycan composition, and internalization into macrophages

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3172711

Dose-response relationships for enzyme replacement therapy with imiglucerase/alglucerase in patients with Gaucher disease type 1.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3172711

Production of glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher's disease using a plant cell system

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3172711

The long-term international safety experience of imiglucerase therapy for Gaucher disease

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3172711

Therapeutic goals in the treatment of Gaucher disease.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3172711

Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3172711

Phase 1/2 and extension study of velaglucerase alfa replacement therapy in adults with type 1 Gaucher disease: 48-month experience

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3172711

Eight-year clinical outcomes of long-term enzyme replacement therapy for 884 children with Gaucher disease type 1.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3172711

A benchmark analysis of the achievement of therapeutic goals for type 1 Gaucher disease patients treated with imiglucerase

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3172711

Analyses of variant acid beta-glucosidases: effects of Gaucher disease mutations

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3172711

Gaucher disease: progressive mesenteric and mediastinal lymphadenopathy despite enzyme therapy

31 August 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21927713

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

A pharmacokinetic analysis of a novel enzyme replacement therapy with Gene-Activated human glucocerebrosidase (GA-GCB) in patients with type 1 Gaucher disease

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21927713

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21927713

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.4155/CLI.10.21

1 reference

2 September 2017

1 reference

PMC publication ID

3172711

2 September 2017

PubMed publication ID

21927713

1 reference

PMC publication ID

3172711